Contents

Highlights of This Issue 6569

SPECIAL FEATURES

CCR Translations

6571  Breast Cancer Treatment with Imiquimod: Applying an Old Lotion to a New Disease
       Holbrook Kohrt
       See articles, p. 6668 and p. 6748

CCR Drug Updates

6574  Cabazitaxel: More Than a New Taxane for Metastatic Castrate-Resistant Prostate Cancer?
       Alain C. Mita, Robert Figlin, and Monica M. Mita

Molecular Pathways

6580  Molecular Pathways: Next-Generation Immunotherpay—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
       Daniel S. Chen, Bryan A. Irving, and F. Stephen Hodi

Review

6588  Do Imaging Biomarkers Relate to Outcome in Patients Treated with VEGF Inhibitors?
       James P.R. O’Connor and Gordon C. Jayson

HUMAN CANCER BIOLOGY

6599  Identification of KIF5B-RET and 60PC-RO5 Fusion in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions
       Yoshiyuki Suehara, Maria Arcila, Lu Wang, Adnan Hasanovic, Daphne Ang, Tatsuo Ito, Yuki Kimura, Alexander Drilon, Udayan Guha, Valerie Rusch, Mark G. Kris, Maureen F. Zakowski, and Marc Ladanyi

CANCER THERAPY: PRECLINICAL

6609  Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia
       Aldo M. Roccaro, Antonio Sacco, Xiaojing Jia, Ranjit Banwait, Patricia Maiso, Feda Azab, Ludmila Flores, Salomon Manier, Abdel Kareem Azab, and Irene M. Ghobrial

6623  Arylsulfonamide KCN1 Inhibits In Vivo Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1α Interaction with Co-factors p300/CBP

6634  HER2-Associated Radiosensitivity of Breast Cancer Stem Cells Isolated from HER2-Negative Breast Cancer Cells
       Nadire Duru, Ming Fan, Demet Candaz, Cheikh Menaa, Hsin-Chen Liu, Danupon Nantajit, Yunfei Wen, Kai Xiao, Angela Eldridge, Brett A. Chromy, Shiyoug Li, Douglas R. Spitz, Kit S. Lam, Max S. Wicha, and Jian Jian Li

6648  Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene Using Liposomal Nanovehicles
       Longjiang Shao, Ibrahim Tekerelere, Jianghua Wang, Erkan Yuca, Susan Tsang, Anil Sood, Gabriel Lopez-Berestein, Bulent Ozpolat, and Michael Ittmann

6658  Translating the Therapeutic Potential of AZD4367 in FGFR1-Amplified Non-Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models
       Jingchuan Zhang, Lin Zhang, Xinying Su, Ming Li, Liang Xie, Florian Mackers, Shutqiong Fan, XiaoLiu Yin, YanPing Xu, Kunji Liu, Zhengwei Dong, Guanshan Zhu, Ziliang Qian, Lili Tang, Ming Fan, Qunseng Ji, Elaine Kilgour, Paul D. Smith, A. Nigel Brooks, Roman K. Thomas, and Paul R. Gavine
Synergy of Topical Toll-like Receptor 7 Agonist with Radiation and Low-Dose Cyclophosphamide in a Mouse Model of Cutaneous Breast Cancer
M. Zahidunnabi Dewan, Claire Vanpouille-Box, Noriko Kawashima, Sara DiNapoli, James S. Babb, Silvia C. Formenti, Sylvia Adams, and Sandra Demaria

A Novel Therapeutic Regimen to Eradicate Established Solid Tumors with an Effect Induction of Tumor-Specific Immunity
James R. Tysome, Xiaozhu Li, Shengdian Wang, Pengju Wang, Dongling Gao, Pan Du, Dong Chen, Rathin Gangeswaran, Louise S. Chard, Ming Yuan, Ghassan Alusi, Nicholas R. Lemoine, and Yaohe Wang

Ethacrynic Acid and a Derivative Enhance Apoptosis in Arsenic Trioxide–Treated Myeloid Leukemia and Lymphoma Cells: The Role of Glutathione S-Transferase P1-1
Rui Wang, Changda Liu, Lijuan Xia, Guisen Zhao, Janice Gabrilove, Samuel Waxman, and Yongkui Jing

miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive Potential In Vitro

Identification of Serum Proton NMR Metabolomic Fingerprints Associated with Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis
Pierre Nahon, Roland Amathieu, Mohamed N. Triba, Nadia Bouchemail, Jean-Charles Nault, Marianne Ziol, Olivier Seror, Gilles Dhonneur, Jean-Claude Trinchet, Michel Beaugrand, and Laurence Le Moyec

Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias
Judith E. Karp, Brian M. Thomas, Jacqueline M. Greer, Christopher Sorge, Steven D. Gore, Keith W. Pratz, B. Douglas Smith, Karen S. Flattten, Kevin Peterson, Paula Schneider, Karen Mackey, Tomoko Freshwater, Mark J. Levis, Michael A. McDevitt, Hetty E. Carraway, Douglas E. Gladstone, Margaret M. Showel, Sabine Lorchner, David A. Parry, Jo Ann Horowitz, Randi Isaacs, and Scott H. Kaufmann

Adoptive Transfer of Autologous T Cells Improves T-cell Repertoire Diversity and Long-term B-cell Function in Pediatric Patients with Neuroblastoma
Stephan A. Grupp, Eline Luning Prak, Jean Boyer, Kenyetta R. McDonald, Suzanne Shusterman, Edward Thompson, Colleen Callahan, Abbas F. Jawad, Bruce L. Levine, Carl H. June, and Kathleen E. Sullivan

Increasing Use of Radical Prostatectomy for Nonlethal Prostate Cancer in Sweden
Ruth Etzioni, Lorelei Mucci, Shu Chen, Jan-Erik Johansson, Katja Fall, and Hans-Olov Adami

Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer
Sylvia Adams, Lina Kozhaya, Frank Martinuk, Tze-Chiang Meng, Luis Chiriboga, Leonard Liebes, Tsivita Hochman, Nicholas Shuman, Deborah Axelson, James Speyer, Yelena Novik, Amy Tiersten, Judith D. Goldberg, Silvia C. Formenti, Nina Bhardwaj, Derya Unutmaz, and Sandra Demaria

See commentary, p. 6571
Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models
Jill M. Spoerke, Carol O'Brien, Ling Huw, Hartmut Koeppen, Jane Fridlyand, Rainer K. Brachmann, Peter M. Haverty, Ajay Pandita, Sankar Mohan, Deepak Sampath, Lori S. Friedman, Leanne Ross, Garret M. Hampton, Lukas C. Amler, David S. Shames, and Mark R. Lackner

Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
Sarat Chandarlapaty, Rita A. Sakr, Dilip Giri, Sujata Patil, Adriana Heguy, Monica Morrow, Shanu Modi, Larry Norton, Neal Rosen, Clifford Hudis, and Tari A. King

Clinicopathologic Features of V600E and V600K Melanoma—Letter
Rosalyn Jewell, Philip Chambers, Mark Harland, Jon Laye, Caroline Conway, Angana Mitra, Faye Elliott, Martin G. Cook, Andy Boon, and Julia Newton-Bishop

Clinicopathologic Features of V600E and V600K Melanoma—Response
Alexander M. Menzies and Georgina V. Long

ABOUT THE COVER
The photomicrograph is of a metastatic, trastuzumab-refractory, HER2-amplified breast cancer with loss of PTEN expression by immunohistochemistry. The normal stromal cells interspersed in the tumor display strong PTEN staining (brown), whereas the cancer cells show complete absence of stain. The primary tumor (pretastuzumab treatment) from this patient showed equivalent PTEN staining in the stromal cells and cancer cells. For details, see the article by Chandarlapaty and colleagues on page 6784 of this issue.
## Clinical Cancer Research

18 (24)

*Clin Cancer Res* 2012;18:6569-6793.

### Updated version

Access the most recent version of this article at:
[http://clincancerres.aacrjournals.org/content/18/24](http://clincancerres.aacrjournals.org/content/18/24)

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, use this link <a href="http://clincancerres.aacrjournals.org/content/18/24">http://clincancerres.aacrjournals.org/content/18/24</a>. Click on &quot;Request Permissions&quot; which will take you to the Copyright Clearance Center's (CCC) Rightslink site.</td>
</tr>
</tbody>
</table>